TeleScope Application on NoviFlow NoviSwitches Uses AI to Enable Real-Time Visibility into Video Flows in Live Networks

Machine Learning and AI can be used for Tier 1 carriers, network infrastructure providers and enterprises to manage video and VR traffic without massive cybersecurity and network management upgrades.”

— Dominique Jodoin, NoviFlow President and CEO

BARCELONA, SPAIN, February 27, 2018 /EINPresswire.com/ — University of New South Wales' Machine Learning-Based Application Combined with NoviSwitches Offers Carriers, ISPs, and Enterprises Unprecedented Price/Performance for Real-Time Video Classification in an Operational Network

NoviFlow Inc., a leading vendor of high-performance OpenFlow-based switching and routing solutions, and UNSW, a world top-100 university with deep expertise in SDN applications that leverage machine learning and artificial intelligence technology, today announced that their joint TeleScope solution is in live trials with network operators.

NoviFlow issued the news from Mobile World Congress #MWC18 Booth 7M11, where the company is demonstrating its solutions.

Carriers and Internet Service Providers (ISPs) worldwide are facing a formidable challenge in coping with the volume of video traffic in their network. Streaming video already accounts for more than half of Internet traffic in most countries. These video flows needlessly drive up the costs of network security appliances by consuming deep-packet inspection and intrusion detection resources even though they are not themselves a direct vector for the propagation of malware and viruses. This situation is only slated to worsen with the growing use of 4K video and Virtual and Augmented Reality applications that will generate yet more video.

The TeleScope application:

— Combines the separation of control and data planes of Software Defined Networks (SDN) with the analytical capabilities of Machine Learning to identify video flows and treat them differently from other large data transfers – such as file transfers – that do need to be examined for malware and other cyber threats.

— Provides carriers and ISPs with the ability to bypass video traffic around expensive network security and packet inspection servers, slashing service delivery costs by up to 60%, reducing management complexity and the impact of new video products and services on existing infrastructure.

— TeleScope leverages NoviFlow's NoviWare NOS, which uses the advanced packet handling capabilities of programmable forwarding planes to significantly boost throughput, offer enhanced filtering options at line rates of 1 Gbps, 10 Gbps, 25 Gbps, 40 Gbps, and 100 Gbps, and support up to 6 million simultaneous flows and up to 6.5 Tbps of packet forwarding capacity on Barefoot Networks' industry leading Tofino chip.

— The NoviWare/Telescope solution was specifically designed to simultaneously support in a single device multiple network services such as switching, routing, service chaining, firewalling, load balancing, etc.

Dominique Jodoin, President and CEO of NoviFlow, said, "The onslaught of video and VR traffic in networks has become a major issue in most large-scale networks. These trials demonstrate how Machine Learning and Artificial Intelligence can be used to enable Tier 1 carriers, network infrastructure providers, and enterprises to face the onslaught without requiring massive upgrades of their cybersecurity and network management resources. We are honored to collaborate with such a distinguished partner as UNSW to offer game-changing Carrier and ISP Services that drive down the costs of running large-scale networks."

Vijay Sivaraman, Professor at UNSW, explained, "Neither hardware-only (middle-boxes) nor software-only (VNF) solutions can perform network functions in a scalable and cost-effective manner to match the growth of traffic in carrier and enterprise networks. SDN enables us to marry the benefits of the two by decoupling forwarding of long-flow packets in hardware from analysis and inference of flow behavior in software. We are very excited to be working with the proven SDN technology and team from NoviFlow to develop and deploy new applications that use AI to enable unprecedented visibility into individual video streams for network operators and scale the solution cost-effectively to high data rates."

ABOUT NOVIFLOW

NoviFlow Inc. provides high-performance OpenFlow-based switching solutions to network carriers, data center operators and enterprises seeking greater control, security and flexibility over their networks. NoviFlow has offices in Montreal, Sunnyvale and Seattle, and representatives in Asia Pacific, Europe and the Middle East. For more information, please visit http://noviflow.com/. Follow NoviFlow on Twitter @NoviFlowInc.

ABOUT UNIVERSITY OF NEW SOUTH WALES

UNSW Sydney is one of Australia's leading research and teaching Universities, ranked 45th in the World by QS and 78th by Times Higher Education. It has produced more technology entrepreneurs in the past 15 years, and more millionaire alumni, than any other Australian University. The Faculty of Engineering is the largest and ranked #1 in Australia, and #31 in the world by QS. The University has a strong history of research in the areas of Telecommunications, software, and artificial intelligence, and is globally recognized for its strong links to industry and commercialization.

Liza Colburn
Crescendo Collaborative Comm for NoviFlow
+1 781.562.0111
email us here


Source: EIN Presswire

Functional Food and Beverage Global Industry 2018 Sales, Supply and Consumption Forecasts to 2025

PUNE, INDIA, February 27, 2018 /EINPresswire.com/ —

Global Functional Food and Beverage Market

WiseGuyRerports.com Presents “Global Functional Food and Beverage Market Research Report 2018” New Document to its Studies Database. The Report Contain 111 Pages With Detailed Analysis.

Description

Global Functional Food and Beverage market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Coca-Cola 
Dannon 
General Mills 
Kellogg 
Kraft Heinz 
Nestle 
PepsiCo 
Red Bul 
Dr. Pepper Snapple Group 
Living Essentials 
MONSTER ENERGY (Monster Beverage Corporation) 
SlimFast 
Yakult USA 
PowerBar 
The Balance Bar Company 
T.C. Pharma 
Wm. Wrigley Jr. Company 

 

Get sample Report @ https://www.wiseguyreports.com/sample-request/3027848-global-functional-food-and-beverage-market-research-report-2018

 

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Functional Food and Beverage in these regions, from 2013 to 2025 (forecast), covering 
North America 
Europe 
China 
Japan 
Southeast Asia 
India 

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into 
Dairy Products 
Bread 
Grain 
Sports Drinks 
Energy Drinks 

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including 
Adult 
Children 
Old Man

Complete Report Details @ https://www.wiseguyreports.com/reports/3027848-global-functional-food-and-beverage-market-research-report-2018

 

Table of Contents -Major Key Points

Global Functional Food and Beverage Market Research Report 2018 
1 Functional Food and Beverage Market Overview 
1.1 Product Overview and Scope of Functional Food and Beverage 
1.2 Functional Food and Beverage Segment by Type (Product Category) 
1.2.1 Global Functional Food and Beverage Production and CAGR (%) Comparison by Type (Product Category)(2013-2025) 
1.2.2 Global Functional Food and Beverage Production Market Share by Type (Product Category) in 2017 
1.2.3 Dairy Products 
1.2.4 Bread 
1.2.5 Grain 
1.2.6 Sports Drinks 
1.2.7 Energy Drinks 
1.3 Global Functional Food and Beverage Segment by Application 
1.3.1 Functional Food and Beverage Consumption (Sales) Comparison by Application (2013-2025) 
1.3.2 Adult 
1.3.3 Children 
1.3.4 Old Man 
1.4 Global Functional Food and Beverage Market by Region (2013-2025) 
1.4.1 Global Functional Food and Beverage Market Size (Value) and CAGR (%) Comparison by Region (2013-2025) 
1.4.2 North America Status and Prospect (2013-2025) 
1.4.3 Europe Status and Prospect (2013-2025) 
1.4.4 China Status and Prospect (2013-2025) 
1.4.5 Japan Status and Prospect (2013-2025) 
1.4.6 Southeast Asia Status and Prospect (2013-2025) 
1.4.7 India Status and Prospect (2013-2025) 
1.5 Global Market Size (Value) of Functional Food and Beverage (2013-2025) 
1.5.1 Global Functional Food and Beverage Revenue Status and Outlook (2013-2025) 
1.5.2 Global Functional Food and Beverage Capacity, Production Status and Outlook (2013-2025)

………

7 Global Functional Food and Beverage Manufacturers Profiles/Analysis 
7.1 Coca-Cola 
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.1.2 Functional Food and Beverage Product Category, Application and Specification 
7.1.2.1 Product A 
7.1.2.2 Product B 
7.1.3 Coca-Cola Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.1.4 Main Business/Business Overview 
7.2 Dannon 
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.2.2 Functional Food and Beverage Product Category, Application and Specification 
7.2.2.1 Product A 
7.2.2.2 Product B 
7.2.3 Dannon Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.2.4 Main Business/Business Overview 
7.3 General Mills 
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.3.2 Functional Food and Beverage Product Category, Application and Specification 
7.3.2.1 Product A 
7.3.2.2 Product B 
7.3.3 General Mills Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.3.4 Main Business/Business Overview 
7.4 Kellogg 
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.4.2 Functional Food and Beverage Product Category, Application and Specification 
7.4.2.1 Product A 
7.4.2.2 Product B 
7.4.3 Kellogg Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.4.4 Main Business/Business Overview 
7.5 Kraft Heinz 
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.5.2 Functional Food and Beverage Product Category, Application and Specification 
7.5.2.1 Product A 
7.5.2.2 Product B 
7.5.3 Kraft Heinz Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.5.4 Main Business/Business Overview 
7.6 Nestle 
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.6.2 Functional Food and Beverage Product Category, Application and Specification 
7.6.2.1 Product A 
7.6.2.2 Product B 
7.6.3 Nestle Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.6.4 Main Business/Business Overview 
7.7 PepsiCo 
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.7.2 Functional Food and Beverage Product Category, Application and Specification 
7.7.2.1 Product A 
7.7.2.2 Product B 
7.7.3 PepsiCo Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.7.4 Main Business/Business Overview 
7.8 Red Bul 
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.8.2 Functional Food and Beverage Product Category, Application and Specification 
7.8.2.1 Product A 
7.8.2.2 Product B 
7.8.3 Red Bul Functional Food and Beverage Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 

 ………..CONTINUED

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Regional Anesthesia Disposables Assessment and Therapeutics Pipeline Review H2 2018

Regional Anesthesia Disposables Therapeutics strategies and Product Pipeline Review 2018

PUNE , INDIA, February 27, 2018 /EINPresswire.com/ — Summary
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Regional Anesthesia Disposables pipeline products.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/reports/3010445-regional-anesthesia-disposables-medical-devices-pipeline-assessment-2018

Scope
– Extensive coverage of the Regional Anesthesia Disposables under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Regional Anesthesia Disposables and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry

Reasons to buy
The report enables you to –
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Regional Anesthesia Disposables under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 Regional Anesthesia Disposables Overview 5
3 Products under Development 6
3.1 Regional Anesthesia Disposables – Pipeline Products by Stage of Development 6
3.2 Regional Anesthesia Disposables – Pipeline Products by Segment 7
3.3 Regional Anesthesia Disposables – Pipeline Products by Territory 8
3.4 Regional Anesthesia Disposables – Pipeline Products by Regulatory Path 9
3.5 Regional Anesthesia Disposables – Pipeline Products by Estimated Approval Date 10
4 Regional Anesthesia Disposables – Pipeline Products under Development by Companies 11
4.1 Regional Anesthesia Disposables Companies – Pipeline Products by Stage of Development 11
4.2 Regional Anesthesia Disposables – Pipeline Products by Stage of Development 12
5 Regional Anesthesia Disposables Companies and Product Overview 13
5.1 Actuated Medical Inc Company Overview 13
5.1.1 Actuated Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 13
5.2 EP Global Communications, Inc. Company Overview 15
5.2.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 15
5.3 Flat Medical Company Overview 16
5.3.1 Flat Medical Pipeline Products & Ongoing Clinical Trials Overview 16
5.4 InSyte Medical Technologies, Inc. Company Overview 17
5.4.1 InSyte Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 17
5.5 Narvitas Medical Devices Limited Company Overview 18
5.5.1 Narvitas Medical Devices Limited Pipeline Products & Ongoing Clinical Trials Overview 18
5.6 Omeq Medical Ltd. Company Overview 19
5.6.1 Omeq Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 19
5.7 Teleflex Inc Company Overview 20
5.7.1 Teleflex Inc Pipeline Products & Ongoing Clinical Trials Overview 20
6 Regional Anesthesia Disposables- Recent Developments 21
6.1 Jan 18, 2018: B. Braun to Showcase Comprehensive Parenteral Nutrition Program, New Compounder and More at ASPEN 21
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3010445-regional-anesthesia-disposables-medical-devices-pipeline-assessment-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Artificial Lung – New Medical Devices For Tracking Lung Cancer Deeply

Artificial Lung

PUNE, MAHARASHTRA, INDIA, February 27, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Artificial Lung – Medical Devices Pipeline Assessment, 2018”

Artificial Lung

Overview:

Medical Devices sector report, “Artificial Lung – Medical Devices Pipeline Assessment, 2018" provides an overview of Artificial Lung currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development.

The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Lung pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by team of experts.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3010453-artificial-lung-medical-devices-pipeline-assessment-2018

Major Key Players are:

ALung Technologies Inc

Breethe, Inc.

Case Western Reserve University

Haemair Ltd

Lung Biotechnology PBC

McGowan Institute for Regenerative Medicine

MedArray Inc.

The Charles Stark Draper Laboratory Inc

University of California San Francisco

University of Michigan

University of Pittsburgh

Xenios AG

Major Scope Of the Report:

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities.

The report reviews the major players involved in the development of Artificial Lung and list all their pipeline projects.

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage. 

The report provides key clinical trial data of ongoing trials specific to pipeline products. 

Recent developments in the segment / industry.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Artificial Lung Overview 6

3 Products under Development 7

3.1 Artificial Lung – Pipeline Products by Stage of Development 7

3.2 Artificial Lung – Pipeline Products by Territory 8

3.3 Artificial Lung – Pipeline Products by Regulatory Path 9

3.4 Artificial Lung – Pipeline Products by Estimated Approval Date 10

3.5 Artificial Lung – Ongoing Clinical Trials 11

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3010453-artificial-lung-medical-devices-pipeline-assessment-2018

 

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Respiratory Assist Devices – Market To Witness Exponential Growth By 2025

Respiratory Assist Devices

PUNE, MAHARASHTRA, INDIA, February 27, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Respiratory Assist Devices – Medical Devices Pipeline Assessment, 2018”

Respiratory Assist Devices

Overview:

Medical Devices sector report, “Respiratory Assist Devices – Medical Devices Pipeline Assessment, 2018" provides an overview of Respiratory Assist Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development.

The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Respiratory Assist Devices pipeline products.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3010451-Respiratory Assist Devices-medical-devices-pipeline-assessment-2018

Major Key Players are:

ALung Technologies Inc

Breethe, Inc.

Case Western Reserve University

enmodes GmbH

Haemair Ltd

Liberate Medical, LLC

Lung Biotechnology PBC

McGowan Institute for Regenerative Medicine

Pneumedicare Ltd.

Rice University

The Charles Stark Draper Laboratory Inc

Major Scope Of the Report:

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities.

The report reviews the major players involved in the development of Respiratory Assist Devices and list all their pipeline projects.

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage. 

The report provides key clinical trial data of ongoing trials specific to pipeline products. 

Recent developments in the segment / industry.

Table of Contents

Table 1: Respiratory Assist Devices – Pipeline Products by Stage of Development 7

Table 2: Respiratory Assist Devices – Pipeline Products by Segment 8

Table 3: Respiratory Assist Devices – Pipeline Products by Territory 9

Table 4: Respiratory Assist Devices – Pipeline Products by Regulatory Path 10

Table 5: Respiratory Assist Devices – Pipeline Products by Estimated Approval Date 11

Table 6: Respiratory Assist Devices – Ongoing Clinical Trials 12

Table 7: Respiratory Assist Devices Companies – Pipeline Products by Stage of Development 13

Table 8: Respiratory Assist Devices – Pipeline Products by Stage of Development 14

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3010451-Respiratory Assist Devices-medical-devices-pipeline-assessment-2018

 

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Nebulizers Market by Medical Device and Ongoing Clinical Trials 2018

Nebulizers

PUNE, MAHARASHTRA, INDIA, February 27, 2018 /EINPresswire.com/ — Nebulizers

Overview:

Medical Devices sector report, “Nebulizers – Medical Devices Pipeline Assessment, 2018" provides an overview of Nebulizers currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development.

The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Nebulizers pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by team of industry experts.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3010451-nebulizers-medical-devices-pipeline-assessment-2018

Major Key Players are:

Aura Medical

Baby's Breath Ltd.

Creare Inc

DesignWise Medical Inc (Inactive)

Marquette University

Parion Sciences Inc

SolAeroMed Inc

Stirling Pharma Inc

University of California San Diego

Major Scope Of the Report:

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities.

The report reviews the major players involved in the development of Nebulizers and list all their pipeline projects.

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage. 

The report provides key clinical trial data of ongoing trials specific to pipeline products. 

Recent developments in the segment/industry.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Nebulizers Overview 7

3 Products under Development 8

3.1 Nebulizers – Pipeline Products by Stage of Development 8

3.2 Nebulizers – Pipeline Products by Segment 9

3.3 Nebulizers – Pipeline Products by Territory 10

3.4 Nebulizers – Pipeline Products by Regulatory Path 11

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3010451-nebulizers-medical-devices-pipeline-assessment-2018

 About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

MatriSys Bioscience Announces Additions to our Scientific Advisory Board

MatriSys Bioscience's Scientific Advisory Board will be joined by three independent, internationally renowned scientists and clinicians

LA JOLLA, CALIFORNIA, USA, February 27, 2018 /EINPresswire.com/ — MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced additions to its Scientific Advisory Board (SAB). MatriSys Bioscience's co-founder, Professor Richard Gallo, Distinguished Professor and Founding Chair of the Department of Dermatology at UCSD and a world leader in the use of microbes as novel medicine will be joined by three independent, internationally renowned scientists and clinicians.

Dr. Lawrence Eichenfield is Professor of Dermatology and Pediatrics, Vice Chair, Department of Dermatology and Chief, Pediatric and Adolescent Dermatology at Rady Children's Hospital, San Diego and at the University of California, San Diego School of Medicine. He earned his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and chief resident at Children's Hospital of Philadelphia before completing dermatology training at the Hospital of the University of Pennsylvania. He is board certified in pediatrics, dermatology, and pediatric dermatology.
Dr. Eichenfield's clinical interests include atopic dermatitis, acne, psoriasis, vascular lesions, neonatal dermatology, laser surgery, and skin signs of systemic disease. He has authored more than 300 journal articles, chapters, abstracts and books on these topics and serves on the editorial boards of several journals and periodicals. Along with being editor-in-chief of Pediatric Dermatology, he has served as senior editor for "Neonatal and Infant Dermatology" and "The Eczemas".
Dr. Eichenfield is past president of the Society for Pediatric Dermatology and has served on the board of the American Academy of Dermatology. He is also a founding board member of the American Acne & Rosacea Society and is a founder and co-chair of the Pediatric Dermatology Research Alliance, a collaborative research network.

Dr. Peter Elias is Professor Emeritus in the Department of Dermatology at the University of California, San Francisco where he serves as the Vice-Chairman of the Department of Dermatology and heads a multidisciplinary research group headquartered at the SF Veteran Affair Medical Center.

Dr. Elias received his medical degree from the University of California, San Francisco. He trained in dermatology at Harvard University and NIH, and in internal medicine at UCSF. Dr. Elias has devoted his research to understanding epidermal biology, focusing primarily on the skin's permeability barrier and its other protective functions. His research is aimed at improving the care of dermatology patients through a better understanding of disease-causing mechanisms and the development of novel therapies with improved safety profiles. He has co-authored over 700 scientific articles and review articles, and three books on the subject of the skin barrier in health and disease.

Dr. Elias has served or currently serves as a consultant to several pharmaceutical and cosmetic industries including J&J, Unilever, Estée Lauder, CHANEL (MAB), L'Oréal, ISDIN (MAB), and Symrise (SAB), and currently to PuraCap Pharma (MAB), Pharmavite (MAB), NeoPharma (SAB), GPower, Patagonia, and Avadim (SAB).

He is the recipient of many honors, including the William Montagna and the Kligman-Frost Awards from the Society of Investigative Dermatology. He is an honorary member of the SID and has been elected to memberships in the American Society for Clinical Investigation and the American Association of Professors.

Dr. Amy Paller is Professor and Chair of Dermatology, Professor of Pediatrics, and Director of Northwestern University Feinberg School of Medicine's Skin Disease Research Center. Dr. Paller is an NIH-funded investigator who currently serves on the NIAMS Board of Scientific Counselors (NIH). Dr. Paller has been President of the Society for Investigative Dermatology, the Women's Dermatologic Society, and the Society for Pediatric Dermatology, and currently is President of the International Eczema Council and the International Society of Pediatric Dermatology. She was the inaugural Co-chair of the Pediatric Dermatology Research Alliance and has been Chair of the Scientific Advisory Board of the National Eczema Association.
Dr. Paller's clinical interests focus on genetic disorders of the skin and cutaneous immunologic disorders in children, including atopic dermatitis. In her laboratory, she studies the role of topically-applied gene suppression using nanoconstructs to treat skin disease with a focus on inflammatory skin disease and diabetic ulcers. Dr. Paller has been the lead investigator on several landmark trials in pediatric skin disease. She is an author of more than 550 journal articles, chapters, and books, and has been on the editorial boards of several journals, including the Journal of Investigative Dermatology and the Journal of the American Academy of Dermatology. She is the recipient of many awards, among them the Rothman Award from the Society for Investigative Dermatology.

On welcoming the members to the SAB, Mark S. Wilson, MatriSys Bioscience's CEO said: "Growing our Scientific Advisory Board represents another important step forward for the company. We have attracted some of the world's leading experts in dermatological diseases as we pursue the development of MSB-01. Importantly, the additions to our SAB are an endorsement of the Company's unique technology platform. These new SAB members bring a wealth of experience across research and clinical trials which will be essential to drive forward the clinical potential of our unique skin microbiome platform for key dermatological indications for which effective therapies are currently limited."

The Scientific Advisory Board will work closely with the MatriSys management team as it actively prepares to advance its lead product candidate, MSB-01, a microbiome-based topical formulation into Phase II B clinical studies. The Company believes MSB-01 has the potential to transform the treatment of atopic dermatitis for the eighteen million American patients.

About MSB-01

MatriSys Bioscience is currently developing MSB-01 which is a commercially viable room-temperature stable topical formulation of freeze-dried S. hominis Strain A9 bacteria in an anhydrous lotion for application to the lesional skin of AD patients. The lyophilized bacteria are revived in the presence of skin moisture and kill S. aureus that colonize the patients' skin. MSB-01 entered Phase 2A in September 2017 (in a frozen formulation).

About MatriSys Bioscience

MatriSys Bioscience is a clinical stage Specialty Biopharmaceutical Company focused on developing and commercializing rational microbiome therapies for the top five dermatology and skin care conditions. Our foundational microbiome therapeutics platform is based on the pioneering work of Richard L. Gallo MD PhD.

Mark S. Wilson
MatriSys Bioscience, Inc.
858.456.3919
email us here


Source: EIN Presswire

San Francisco, California Doctor Selected to the "America's Best Physicians" 2018 Directory

Dr. Ella G. Faktorovich

Dr. Ella G. Faktorovich, MD listed as Top Doctor in Ophthalmology & Eye Surgery

Dr. Ella G. Faktorovich Selected as Top Doctor in Ophthalmology & Eye Surgery”

— TodaysBestPhysicians.com

SAN FRANCISCO , CALIFORNIA, UNITED STATES, February 26, 2018 /EINPresswire.com/ — San Francisco, California doctor, Dr. Ella G. Faktorovich has been selected to the "America's Best Physicians" registry for 2018. Selections were made by the National Consumer Advisory Board, an organization that identifies top professionals in their fields.

Dr. Faktorovich practices Ophthalmology at 505 Beach Street, Suite 110 in San Francisco serving patients in San Francisco, Marin, Peninsula and surrounding areas.

Services include: Refractive surgery, Laser Vision Correction, LASIK, Photorefractive keratectomy (PRK), Advanced Cataract Surgery, Transplants, Collagen Cross-Linking, Corneal and Presbyopia Surgery.

Dr. Ella G. Faktorovich graduated Phi Beta Kappa from UC Berkeley. She received her Medical Degree with honors from University of California, San Francisco (UCSF) School of Medicine. She completed her Ophthalmology Residency at UCSF Department of Ophthalmology. She then received two years of advanced training in Laser and Refractive Surgery at the Jules Stein Eye Institute, UCLA School of Medicine.

Dr. Faktorovich has received numerous honors and completed award-winning research. She has published numerous articles, book chapters and abstracts and has lectured extensively. Dr. Faktorovich is the Founder and Chairman of the annual San Francisco Cornea, Cataract, and Refractive Surgery Symposium and the Pacific Vision Institute Research Foundation. She continues to teach Advanced Surgical Techniques to her peers and lecture worldwide.

Dr. Ella G. Faktorovich is a member of American Academy of Ophthalmology, California Medical Association, San Francisco Medical Society, Association for Research in Vision and Ophthalmology, International Society of Refractive Surgery and the American Society of Cataract and Refractive Surgery. She is Board Certified and has earned Fellowship status by the American Board of Ophthalmology. Dr. Faktorovich has been in practice for over 20 years.

For more information, please go to www.TodaysBestPhysicians.com or contact Dr. Ella G. Faktorovich, MD directly at 415-922-9500.

The "National Consumer Advisory Board" accepts no fees, sponsorships, donations or advertising in their selection process. Doctors were chosen following an application based on training, experience, continuing education, and dedication to excellence. Only Doctors that satisfy all of the board's criteria can qualify for inclusion in the "Americas Best Physicians" directory.

TodaysBestPhysicians.com
Americas Best Physicians
5555555555
email us here


Source: EIN Presswire

World Human Albumin Industry: 2018 Market Size, Share, Uses, Applications, Key Manufacturers and 2025 Demand Forecast

Human Albumin Market 2018

Global Human Albumin Market Research Report 2018

Latest research report on “Global Human Albumin Market 2018 Research Report ” now available at a high quality database of OrianResearch.com

PUNE, MAHARASHTRA, INDIA, February 26, 2018 /EINPresswire.com/ — The Global Human Albumin Market was valued at USD XX million in 2017 and is expected to be valued at USD XX Billion by 2025, at a CAGR of XX % during the forecast period. The growth of the Global Human Albumin Market is largely driven by the continuous research and development in albumin which led to many therapeutic as well as non-therapeutic applications such as stabilizing Alzheimers disease.

Get Sample Copy of this Report at – https://www.orianresearch.com/request-sample/461019 .

Global Human Albumin Market is segmented by Application and Region.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Complete report on Human Albumin Industry spread across 119 pages, profiling 07 companies and supported with tables and figures. Enquire for more at – https://www.orianresearch.com/enquiry-before-buying/461019 .

Top Key Companies Analyzed in Global Human Albumin Market are –
• CSL Behring
• Baxalta
• Kedrion
• Grifols
• Octapharma AG
• Biotest
• Green cross

Key benefit of this report:
• This report provides current market trends and future growth expectations.
• This report examines the market size and changing competitive dynamics
• It covers information regarding key drivers, challenges or restraining market growth
• Market factor analysis delivers treasured information regarding the possible purchasers and suppliers and understanding the stakeholders involved.
• This report incorporates data regarding companies and business decision by having complete insights on the markets and by creating in depth analysis of market segments.

Target Audience
• Albumin product developers
• Hospitals and Research Laboratories
• Pharmaceutical and biotechnology companies
• Distributors and suppliers
• Government organizations

Get Direct Copy of this Report @ https://www.orianresearch.com/checkout/461019 .

Major Points Covered in Table of Contents:
1. Executive Summary
2. Demographic Overview
3. Research Methodology
4. Premium Insights
5. Market Overview
6. Market Factor Analysis
7 Global Human Albumin Market By Application
8 Global Human Albumin Market By Region
9 Market Trends & Competitive Analysis
10 Company Profiles
Author List
Disclosure Section
Research Methodology
Data Source

Ruwin Mendez
OrianResearch Consultants
+1 832-380-8827
email us here


Source: EIN Presswire

Spotswood, New Jersey Dentist Selected to the "America's Best Dentists" 2018 Directory

Dr. Matthew Sorkin

Dr. Matthew Sorkin, DDS, FAGD Listed as Top Dentist in Family, Cosmetic, Implant & Sedation Dentistry

Dr. Matthew Sorkin Selected as Top Dentist in Family, Cosmetic, Implant & Sedation Dentistry”

— TodaysBestDentists.com

SPOTSWOOD , NEW JERSEY , UNITED STATES, February 26, 2018 /EINPresswire.com/ — Spotswood, New Jersey dentist, Dr. Matthew Sorkin has been selected to the "America's Best Dentists" registry for 2018. Selections were made by the National Consumer Advisory Board, an organization that identifies top professionals in their fields.

Dr. Sorkin practices Family, Cosmetic, Implant & Sedation Dentistry at 418 Main St. in Spotswood serving patients in Monroe Twp. Helmetta, Old Bridge, Spotswood, and East Brunswick.

Services include: Cosmetic Dentistry, Dental Implants, Planscan/E4D Same Day Crowns, Air-Brush No-Drill Fillings, Laser Gum Therapy, Oral Sedation Dentistry, Root Canal Treatment, Tooth Colored Fillings, and Teeth Whitening.

Dr. Sorkin received his doctorate of dental surgery degree (DDS) from Columbia University School of Dental Medicine. He then performed a General Practice Residency at Hackensack University Medical Center. He continues to be quite active in postgraduate education earning him Fellowship Status in the Academy of General Dentistry.

Dr. Matthew Sorkin is a member of the American Dental Association, New Jersey Dental Association and Middlesex County Dental Society. During his 25 years in practice Dr. Sorkin has become well-known for providing highly personal, state-of-the-art care at the highest level.

For more information, please go to www.TodaysBestDentists.com or contact Dr. Matthew Sorkin, DDS directly at 732-723-5100 or www.caringdentalspotswood.com.

The "National Consumer Advisory Board" accepts no fees, sponsorships, donations or advertising in their selection process. Dentists were chosen following an application based on training, experience, continuing education, and dedication to excellence. Only Dentists that satisfy all of the board's criteria can qualify for inclusion in the "Americas Best Dentists" directory.

TodaysBestDentists.com
Americas Best Dentists
5555555555
email us here


Source: EIN Presswire